文献速递中枢神经肿瘤放疗胸部肿瘤放疗

放疗在非小细胞肺癌脑转移管理中的作用——临床常规决策标准

Role of radiotherapy in the management of brain metastases of NSCLC - Decision criteria in clinical routine.
PubMed 文献 · Radiother Oncol · 2020-11-11

研究分析欧洲放射肿瘤专家对非小细胞肺癌脑转移的决策标准,识别出8项决策标准,多数专家推荐对不适合立体定向放疗的症状性患者使用全脑放疗,且在ALK/EGFR/ROS1阴性时倾向使用全脑放疗。尽管QUARTZ试验提示部分患者可省略全脑放疗,但全脑放疗在欧洲专家中仍广泛使用。

要点

  • 识别出8项决策标准:SRS适用性、体能状态、症状、靶向治疗资格、颅外肿瘤控制、年龄、预后评分和「被迫治疗」。
  • 多数欧洲专家推荐对不适合放疗外科或分次立体定向放疗的症状性患者使用全脑放疗。
  • 在ALK/EGFR/ROS1阴性非小细胞肺癌中,专家倾向于使用全脑放疗。

核心结论

  • 尽管QUARTZ试验结果表明全脑放疗可在部分患者中省略,但全脑放疗在欧洲放射肿瘤专家中仍被广泛使用。

主要发现

  • 识别出8项决策标准:SRS适用性、体能状态、症状、靶向治疗资格、颅外肿瘤控制、年龄、预后评分和「Zugzwang」(被迫治疗)。
  • 多数欧洲专家推荐对不适合放疗外科或分次立体定向放疗的症状性患者使用全脑放疗。
  • 在ALK/EGFR/ROS1阴性非小细胞肺癌中,专家倾向于使用全脑放疗。

关键数值与推荐

  • 8项决策标准:SRS适用性、体能状态、症状、靶向治疗资格、颅外肿瘤控制、年龄、预后评分和「Zugzwang」(被迫治疗)。
  • 多数专家推荐对不适合放疗外科或分次立体定向放疗的症状性患者使用全脑放疗。
  • 在ALK/EGFR/ROS1阴性非小细胞肺癌中倾向使用全脑放疗。

临床怎么用

  • 临床决策可参考SRS适用性、体能状态、症状、靶向治疗资格、颅外肿瘤控制、年龄、预后评分和「Zugzwang」等标准选择全脑放疗。
  • 对不适合放疗外科或分次立体定向放疗的症状性患者,多数欧洲专家推荐全脑放疗。
  • 在ALK/EGFR/ROS1阴性非小细胞肺癌中,可考虑倾向使用全脑放疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whole brain radiotherapy (WBRT) is a common treatment option for brain metastases secondary to non-small cell lung cancer (NSCLC). Data from the QUARTZ trial suggest that WBRT can be omitted in selected patients and treated with optimal supportive care alone. Nevertheless, WBRT is still widely used to treat brain metastases secondary to NSCLC. We analysed decision criteria influencing the selection for WBRT among European radiation oncology experts. METHODS: Twenty-two European radiation oncology experts in lung cancer as selected by the European Society for Therapeutic Radiation Oncology (ESTRO) for previous projects and by the Advisory Committee on Radiation Oncology Practice (ACROP) for lung cancer were asked to describe their strategies in the management of brain metastases of NSCLC. Treatment strategies were subsequently converted into decision trees and analysed for agreement and discrepancies. RESULTS: Eight decision criteria (suitability for SRS, performance status, symptoms, eligibility for targeted therapy, extra-cranial tumour control, age, prognostic scores and "Zugzwang" (the compulsion to treat)) were identified. WBRT was recommended by a majority of the European experts for symptomatic patients not suitable for radiosurgery or fractionated stereotactic radiotherapy. There was also a tendency to use WBRT in the ALK/EGFR/ROS1 negative NSCLC setting. CONCLUSION: Despite the results of the QUARTZ trial WBRT is still widely used among European radiation oncology experts.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Glatzer M, Faivre-Finn C, De Ruysscher D, et al. Role of radiotherapy in the management of brain metastases of NSCLC - Decision criteria in clinical routine. Radiother Oncol. 2020. PMID: 33186683. doi:10.1016/j.radonc.2020.10.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。